To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Already have an account?
Protelica Awarded Phase II SBIR Grant by the National Science Foundation
Read time: 1 minute
Protelica (formerly known as ProtElix, Inc.) has announced that it has received formal notification of Phase II SBIR funding by the National Science Foundation for its scientific project entitled “Bioinformatics knowledge-based, universal library design for a non-immunoglobulin, protein-scaffold.”
The grant, effective January 15, 2009 provides $500,000 for the next 24 months and will allow the Company to continue developing its platform technology, and to fund preclinical studies of its early stage lead candidates for cardiovascular and cancer therapies.
“We are very grateful to NSF for acknowledging our research project as one of the most innovative in the country and for supporting the development of new protein therapeutics that may replace the first generation monoclonal antibody drugs,” states Dr. Roberto Crea, Protelica’s Founder, CEO and Chief Scientific Officer.
“We believe our approach to antibody mimics discovery and optimization will lead to new therapeutics that may be more effective and less expensive. We are pleased to receive the validation of this peer-reviewed grant,” adds Dr. Crea.
The project, which started two years ago, includes a bioinformatics-based understanding of nature’s evolutionary rules, and utilizes Protelica’s proprietary DNA mutagenesis technologies to develop small, specific and potent protein blockers.
“By understanding how nature evolves its protein binding specificity, we are able to introduce new and ‘intelligent’ diversity to human protein scaffolds, like Fibronectin sub-units, and generate billions of new variants. We expect this program to lead to the discovery and clinical development of new protein drugs that combine the exquisite specificity of antibodies with the many clinical and manufacturing advantages typical of small molecules,” explains Dr. Guido Cappuccilli, the project’s Principal Investigator and head of the Bioinformatics Group at Protelica.
The grant, effective January 15, 2009 provides $500,000 for the next 24 months and will allow the Company to continue developing its platform technology, and to fund preclinical studies of its early stage lead candidates for cardiovascular and cancer therapies.
“We are very grateful to NSF for acknowledging our research project as one of the most innovative in the country and for supporting the development of new protein therapeutics that may replace the first generation monoclonal antibody drugs,” states Dr. Roberto Crea, Protelica’s Founder, CEO and Chief Scientific Officer.
“We believe our approach to antibody mimics discovery and optimization will lead to new therapeutics that may be more effective and less expensive. We are pleased to receive the validation of this peer-reviewed grant,” adds Dr. Crea.
The project, which started two years ago, includes a bioinformatics-based understanding of nature’s evolutionary rules, and utilizes Protelica’s proprietary DNA mutagenesis technologies to develop small, specific and potent protein blockers.
“By understanding how nature evolves its protein binding specificity, we are able to introduce new and ‘intelligent’ diversity to human protein scaffolds, like Fibronectin sub-units, and generate billions of new variants. We expect this program to lead to the discovery and clinical development of new protein drugs that combine the exquisite specificity of antibodies with the many clinical and manufacturing advantages typical of small molecules,” explains Dr. Guido Cappuccilli, the project’s Principal Investigator and head of the Bioinformatics Group at Protelica.
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
